Abstract
A plenitude of reasons, including tumour heterogeneity, mechanisms of resistance to therapy, a complex pathogenesis, in which cancer stem cells are involved, contribute to the poor outcome of HNSCC patients after therapy. The roles of vital signalling proteins are constantly unravelled, and different types of inhibitors are examined yielding novel potential targeting strategies. However, there will be a long way to go, before drugs targeting these molecules will be available in routine clinical practice. In this review the focus will be on these novel targets, as well as inhibiting agents, which nowadays are combined to an increasing degree. Additionally, the role proteomics plays in modern drug research will be highlighted.
Keywords: Cancer stem cells, epithelial-to-mesenchymal transition, HNSCC, proteomics, targeted therapy.
Current Proteomics
Title:Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Volume: 10 Issue: 2
Author(s): Eva-Maria Schottdorf
Affiliation:
Keywords: Cancer stem cells, epithelial-to-mesenchymal transition, HNSCC, proteomics, targeted therapy.
Abstract: A plenitude of reasons, including tumour heterogeneity, mechanisms of resistance to therapy, a complex pathogenesis, in which cancer stem cells are involved, contribute to the poor outcome of HNSCC patients after therapy. The roles of vital signalling proteins are constantly unravelled, and different types of inhibitors are examined yielding novel potential targeting strategies. However, there will be a long way to go, before drugs targeting these molecules will be available in routine clinical practice. In this review the focus will be on these novel targets, as well as inhibiting agents, which nowadays are combined to an increasing degree. Additionally, the role proteomics plays in modern drug research will be highlighted.
Export Options
About this article
Cite this article as:
Schottdorf Eva-Maria, Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials, Current Proteomics 2013; 10 (2) . https://dx.doi.org/10.2174/1570164611310020007
DOI https://dx.doi.org/10.2174/1570164611310020007 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathology of the HPV-associated Oropharyngeal Carcinoma
Current Cancer Therapy Reviews Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions
Current Medicinal Chemistry COX-2, Cell Proliferation and PMA in Head-and-Neck Cancer Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Advancement of Targeted Ultrasound Contrast Agents and their Applications in Molecular Imaging and Targeted Therapy
Current Pharmaceutical Design Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis
MicroRNA RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
Current Cancer Therapy Reviews Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Phosphorylation-Specific Prolyl Isomerase Pin1 as a new Diagnostic and Therapeutic Target for Cancer
Current Cancer Drug Targets Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Development of Genomics-Based Gene Expression Signature Biomarkers in Oncology and Toxicology to Facilitate Drug Discovery and Translational Medicine
Current Bioinformatics